Novartis Secures Global Rights to Chinese mRNA Therapy ABO2203 in Deal Worth Up to $7.8 Billion

Novartis pays Abogen $575M upfront for global rights to mRNA-encoded T-cell engager ABO2203, with milestones that could reach $7.2B.

Novartis has moved to replenish its immunology pipeline with an in-licensing agreement that could ultimately be worth $7.8 billion, striking a worldwide exclusive licensing and option deal with Chinese biotech Abogen Biosciences for the mRNA-encoded T-cell engager ABO2203.

The Basel-based drugmaker will pay Abogen a fixed upfront sum of $575 million for global exclusive rights to the candidate, along with options on additional research programs. Success-based milestone payments tied to development, regulatory and commercial targets could add as much as $7.2 billion, with royalties on future product sales layered on top. The transaction remains subject to customary closing conditions and regulatory clearances.

At the center of the partnership sits ABO2203, a messenger-RNA-encoded T-cell engager directed at the CD19 and CD3 surface proteins. The therapeutic approach harnesses the body's own T-cells to eliminate misdirected B-cells, which play a central role in the onset of severe autoimmune conditions. The same class of compounds is also being explored in oncology.

Early Data Underpin the Mechanism

Clinical evidence gathered so far lends support to the molecule's mode of action. At the AACR cancer research congress, investigators presented Phase 1 results from nine patients with relapsed or refractory B-cell non-Hodgkin lymphoma. In the highest dose cohort, the candidate achieved an objective response rate of up to 100 percent, with no cases of cytokine release syndrome or neurological complications. Adverse events documented in three trial participants resolved as treatment continued. A separate Phase 1 study is underway in 66 planned adult patients with autoimmune diseases.

For Novartis, the deal secures access to a platform that could complement conventional cell therapies through mRNA-based mechanisms. It also reflects a shifting landscape in pharmaceutical R&D. According to forecasts from research firm ING, China is expected to account for roughly one third of all new molecules in global pharma pipelines by 2026, up from just 4 percent in 2014.

The agreement lands after a difficult late summer for the Swiss group. Two late-stage clinical trials failed in September, temporarily wiping almost $30 billion from the company's market value. Novartis has nonetheless continued to sharpen its focus on innovative platform technologies. Roughly two weeks ago, the company received a positive CHMP recommendation for Cosentyx in the treatment of polymyalgia rheumatica.

Market Response Muted

Investors greeted the new financial commitments with restraint. Novartis shares closed Friday at EUR 125.16, a modest decline of 0.4 percent, leaving the stock down 10 percent over the past 30 days. Market participants weighed the long-term promise of the research approach against the upfront cash outlay and development risks. On the analyst side, Deutsche Bank reaffirmed its hold rating on September 29, keeping its price target unchanged at CHF 120.

Whether the hefty milestone commitments pay off will depend on how the remaining study phases unfold. Measured against its 52-week low of EUR 104.56, the stock still holds a gain of 20 percent despite the recent pullback. Upcoming clinical readouts on ABO2203 are likely to determine how viable the approach proves relative to competing strategies for immune modulation.

Attention now turns to concrete operating figures. Novartis has said it will publish detailed results for the third quarter and the first nine months of the 2026 financial year on October 27. Beyond revenue from established medicines, strategic research spending is expected to draw close scrutiny from market observers.